Abstract: The present disclosure relates to texaphyrin compounds linked with an antitumor antibiotic such as an anthcyanine antitumor antibiotic such as doxorubicin and danurubicin. The texaphyrin and the antitumor antibiotic are joined together by a group which is cleavable in vivo and results in increased activity and deliverance of the cytotoxic compound to target cells. Also provided herein are pharmaceutical compositions and methods of use thereof.

Abstract: The invention relates to invention relates to a statistical copolymer represented by the following formula (I): Ini-[Ox]m-[Oz]n-Nuc (I) wherein: Ini represents a residue of an initiator of cationic polymerization, Nuc represents a residue of a nucleophilic agent, Ox represents N(R1)CHRaCHRa; each R1 independently represents H or C(O)R11; and R11 independently represents optionally substituted C1-12 alkyl, optionally substituted cycloalkyl, optionally substituted aralkyl or optionally substituted aryl; Oz represents N(R2)CHRaCHRaCHRa; each R2 independently represents C(O)R21 or H; and R21 independently represents optionally substituted C1-12 alkyl, optionally substituted cycloalkyl, optionally substituted aralkyl or optionally substituted aryl; each Ra independently represents H, linear or branched C1-3 alkyl; m?5; n?5; m+n?20; 3:97?m:n?97:3.

Abstract: A bone filling composition includes a bone filler. The bone filler includes microparticles of at least one elastomeric material. The at least one elastomeric material includes a poly(glycerol sebacate)-based thermoset. The poly(glycerol sebacate)-based thermoset may be porous thermoset poly(glycerol sebacate) flour, thermoset poly(glycerol sebacate) microspheres, or a combination thereof. In some embodiments, the bone filling composition is a bone filling composite that further includes a carrier material including a poly(glycerol sebacate) resin. A method of forming a bone filling composite includes selecting a bone filler and mixing the bone filler with a carrier material to form the bone filling composite. A method of treating a bony defect includes molding a bone filling composite and placing the bone filling composite in the bony defect. The bone filling composite includes a bone filler mixed with a carrier material.

Abstract: Described herein are compounds, compositions and methods for modification of the surface of a living cell with a therapeutically relevant targeting moiety. Also described herein are methods for treating disease states, such as acute myocardial ischemia or infarction, with said compositions, in a subject.

Abstract: The present disclosure provides compositions for inducing immune tolerance and methods to modify antigen to treat disease such as autoimmune diseases and allergy. Disclosed are compositions, and related methods, comprising APC presentable antigens and immunosuppressants that provide tolerogenic immune responses specific to antigen. In some embodiments, the composition is used for transdermal delivery.

Abstract: The present disclosure provides a method for treating a patient having cancer, such as glioblastoma. The method may comprise obtaining a biological sample from the patient, and detecting a mutation in a microtubule-related gene is present in the biological sample. The method further comprises administering an effective amount of a pharmaceutical composition comprising a tubulin polymerization inhibitor, such as an auristatin, to the patient.

Abstract: The disclosure provides a process of designing and optimizing supramolecular therapeutics. The disclosure also provides a method for designing and optimizing antibody drug conjugates.

Abstract: A bifunctional polypeptide comprising a specific binding partner for a peptide-MHC epitope, such as an antibody or T cell receptor, and an immune effector, such as an antibody or a cytokine, the immune effector part being linked to the N-terminus of the peptide-MHC binding part.

Abstract: A bifunctional polypeptide comprising a specific binding partner for a peptide-MHC epitope, such as an antibody or T cell receptor, and an immune effector, such as an antibody or a cytokine, the immune effector part being linked to the N-terminus of the peptide-MHC binding part.

Abstract: A platinum(II) complex loaded on a mesosilicalite nanocarrier having a hierarchical silicalite characterized by a molar ratio of aluminum to silica in a range of 1:3000 to 1:1000. The hierarchical silicalite includes mesopores of a hexagonal structure, and micropores of silicalite structure with a microporous volume in the range of 0.05 cc/g to 0.1 cc/g. The mesosiliclite nanocarrier loaded with the platinum(II) complex is suitable for treatment of cancer, in particular, breast, cervical, and colon cancers.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating an inflammatory disease and a metabolic disease, which includes hyaluronic acid nanoparticles, and more particularly, to a pharmaceutical composition for preventing or treating an inflammatory disease and a metabolic disease, which includes hyaluronic acid nanoparticles formed in such a way that 5?-cholanic acid or polycaprolactone binds to a hydrophobic moiety of hyaluronic acid through self-assembly in an aqueous solution state.

Abstract: An expression cassette for gene silencing and replacement, including, in operable communication, a promoter, an expression attenuator, a nucleotide sequence encoding a gene for a replacement target protein, and an shRNA sequence for knockdown of an endogenous variant of the target protein, wherein the promoter, the expression attenuator, the nucleotide sequence encoding the gene for the replacement target protein, and the shRNA are expressed as a single transcript. Also included are expression vectors and cells. Also included are methods of silencing and replacement of a target gene in a cell in culture by transforming the cells with the expression vectors described herein. Also included are minimal expression cassettes suitable for therapeutic methods.

Abstract: The present invention provides new adeno-associated virus-derived vectors and pharmaceutical compositions containing the same for the treatment of lysosomal storage disorders and specially, for the treatment of mucopolysaccharidoses Type IIID.

Abstract: Provided herein are adeno-associated virus (AAV) compositions that can express a phenylalanine hydroxylase (PAH) polypeptide in a cell, thereby restoring the PAH gene function. Also provided are methods of use of the AAV compositions, and packaging systems for making the AAV compositions.

Abstract: Aspects of the application relate to methods and compositions for delivering therapeutic nucleic acids to neural cells or tissue in a subject. Additional aspects of the application relate to therapeutic nucleic acids, for example therapeutic ribozymes, that are useful for inhibiting viral reactivation in a subject.

Abstract: Described herein are particle-driven radiogenomics systems and methods that can be used to identify imaging features for prediction of intratumoral and interstitial nanoparticle distributions in cancers (e.g., in low grade and/or high-grade brain cancers (e.g., gliomas, e.g., primary gliomas)). In certain embodiments, the systems and methods described herein extract and combine quantitative multi-dimensional data generated from structural, functional, and/or metabolic imaging. In certain embodiments, the combined multidimensional data is linked to intratumoral and interstitial nanoparticle distributions. For example, this linked data can be used to determine quantitative functional-metabolic multimodality particle-based imaging features and to predict treatment efficacy. These techniques provide an improved quantitative ability to measure treatment response and determine tumor progressions compared to traditional size-based imaging methods.

Abstract: The present subject matter provides compounds, compositions, and methods for identifying, monitoring, treating, and removing diseased tissue. Compounds, compositions, and methods for identifying, monitoring, and detecting circulating fluids such as blood are also provided.

Abstract: Disclosed is a method of non-invasive infrared imaging, comprising (a) administering a composition containing infrared-emitting particles which contain rare earth elements that emit in the short-wavelength infrared (SWIR) spectrum, where the particles are encapsulated with a biocompatible matrix to form downconverting encapsulated particles; and (b) irradiating with infrared radiation, where both excitation and emission spectra of the encapsulated particles are in the infrared region. Analogous methods of image-guided biomedical intervention, and drug tracking and delivery are also disclosed. Also disclosed is a composition for biomedical applications, containing infrared-emitting particles which contain rare earth-elements that emit in the short-wavelength infrared (SWIR) spectrum, where the particles are encapsulated with a biocompatible matrix to form downconverting encapsulated particles.

Abstract: The present invention relates to the use of in vivo contrast agents in medical imaging in order to diagnose and treat disease, and to monitor and assess disease progression following treatment with a nanoparticle therapeutic agent comprising an active pharmaceutical agent. The present invention also relates to modulating nanoparticle tumor concentration by modulating the PEG density of the nanoparticles.

Abstract: Provided herein are magnetic resonance imaging (MRI) contrast agents comprising a compound having a structure represented by: Y—X—Z, wherein, X is: Fe(III) or Mn(II), and Y and Z are each independently selected from pyrophosphate and bisphosphonate (e.g., 1-hydroxybisphosphonate), or a pharmaceutically acceptable hydrate and/or salt thereof. Methods of use of the MRI contrast agent are also provided.

Abstract: Radiopaque monomers, polymers, and microspheres are disclosed herein. Methods of using the radiopaque monomers, polymers, and microspheres are disclosed herein. Methods of manufacturing radiopaque monomers, polymers, and microspheres are disclosed herein.

Abstract: A compound comprising an oligomer formed from a biocompatible multifunctional carboxylic acid comprising a hydroxyl group and at least one carboxylic acid, an polyol (e.g., an aliphatic diol), and a linker. One or more conductive oligomers (e.g., polyanilines) are covalently bonded to the oligomer. The compounds can have various forms (e.g., articles of manufacture, films, scaffolds, and the like). The compounds have various uses. For example, the compounds are used in photoacoustic imaging methods.

Abstract: Novel cromolyn analogs useful as imaging agents for detecting atherosclerotic plaques and for treating atherosclerosis and Alzheimer's Disease, and methods of making the cromolyn analogs, are disclosed. The cromolyn analogs have the general formula: wherein: X is OH, C1-C6 alkoxyl; Y and Z are independently selected form a C1-C6 alkyl, C1-C6 alkoxyl, halogen, un-substiuted or C1-C6 substituted amine, 18F, 19F, or H; and n is 1, 2, or 3; and wherein for structure (I), if n are both 1 and Y and Z are both H and X is OH.

Abstract: Compositions that are suitable for use as a disinfectant are disclosed. Methods of making and using compositions that are suitable for use as a disinfectant are also disclosed.

Abstract: Aspects of the invention provide a system for disinfecting a humidifier containing a volume of water. An enclosure, such as a humidifier, includes a first chamber, a second chamber, a humidifier component, a third chamber, and a control unit. The first chamber contains a volume of water and a portion of the water flows into the second chamber. A first set of ultraviolet radiation sources within the first chamber can be configured to generate UV-A radiation, while a second set of ultraviolet radiation sources within the second chamber can be configured to generate UV-C radiation. In operation, the humidifier component adjacent to the second chamber creates water vapor using the portion of the volume of water within the second chamber. The water vapor flows into a third chamber that contains the water vapor and releases the water vapor into the ambient.

Abstract: The invention relates to the sterilization of a load of goods with hydrogen peroxide vapor in a closed space. The method involves a sequence of creating a sub-atmospheric pressure in a sterilization chamber, introduction of vaporized hydrogen peroxide and the use of a gas circulation device within the sterilization chamber, whereby the output of the gas circulation device is controlled according to the pressure in the sterilization chamber. A uniform and consistent distribution of hydrogen peroxide throughout the load is achieved.

Abstract: A hybrid packet containing deodorizing chemicals can dissolve to release the chemicals in a brine solution while still being formed using high speed packet forming machinery. A hybrid packet can be formed by feeding a sheet of dissolvable paper and a film of PVA material into the packet forming machine to form a hybrid packet having one side formed of the paper and the opposing side formed of the PVA material. The PVA sheet and paper panels are fused together by the machine to form a sealed interior compartment that holds the deodorizing chemicals. A serrated knife edge can be used to pierce the paper and PVA layers to separate individual packets. Reduced water volume in the forming operation avoids compromising the dissolvable paper portion of the hybrid packet. The packet contents can include citric acid and sodium bicarbonate.

Abstract: Articles can be provided with odor resistance by applying a dispersion of a halogenated heterocyclic N-halamine in an inert liquid carrier onto the surface of the article and allowing the inert liquid carrier to penetrate into it. The N-halamine accordingly becomes deposited on the surface of the article after the inert liquid carrier penetrates into the article. This method can be used to provide odor resistance to a variety of substrates, including garbage bags. It can also be used to deposit other functional particulates onto the surface of substrates having sufficient porosity to take up the vehicle. For instance, such functional particles can be oxidants that display antimicrobial and/or enzyme inhibitory efficacy or particles having toxin interaction potentials through oxidative degradation or adsorption of toxic substances in air and/or water, such as fluoride uptake by metal oxide microparticles.

Abstract: Articles can be provided with odor resistance by applying a dispersion of a halogenated heterocyclic N-halamine in an inert liquid carrier onto the surface of the article and allowing the inert liquid carrier to penetrate into it. The N-halamine accordingly becomes deposited on the surface of the article after the inert liquid carrier penetrates into the article. This method can be used to provide odor resistance to a variety of substrates, including garbage bags. It can also be used to deposit other functional particulates onto the surface of substrates having sufficient porosity to take up the vehicle. For instance, such functional particles can be oxidants that display antimicrobial and/or enzyme inhibitory efficacy or particles having toxin interaction potentials through oxidative degradation or adsorption of toxic substances in air and/or water, such as fluoride uptake by metal oxide microparticles.

Abstract: Disclosed is a volatile liquid dispensing system that includes a dispenser and a refill unit. The dispenser is mounted on a predefined surface. The dispenser includes a front cover and a rear cover. The refill unit is removably secured inside the dispenser thereby maintaining a predefined gap therebetween. The refill unit includes a refill cover. The refill cover includes a fragrance reservoir and a collection device enclosed therein. The fragrance reservoir is formed by a gas shell and a fragrance shell. The fragrance reservoir is positioned in a predefined orientation with respect to the mounting surface. The collection device is positioned adjacent to the fragrance reservoir such that a predefined gap is maintained therebetween. The collection device is enclosed in the refill cover such that a predefined gap is maintained therebetween thereby allowing evaporation of the volatile liquid from all sides of the collection device.

Abstract: A human-activity-environment air-purifying apparatus is provided that draws in airflow from an ambient environment, kills germs in the airflow within the apparatus and expels purified airflow back into the environment. The apparatus has a housing with an interior chamber. An airflow enters the chamber through an inlet. From the interior chamber, the airflow is expelled through an outlet. The apparatus has a germ-killing-system that kills germs in the airflow and has an airflow-generator which causes the airflow to flow from the inlet to the outlet. In one aspect, the apparatus has a three-dimensional filter structure that has air-filter-surfaces that define a filter interior region and encompassed by the air-filter-surfaces of the filter structure. The filter is positioned in connection with the inlet so that airflow entering the inlet is dispersed into the housing interior chamber in multiple directions exclusively through the air-filter-surfaces of the three-dimensional filter structure.

Abstract: Described are articles formed of a pulp base material comprising fibers, wherein pores are formed between the fibers. A volatile composition with at least one top note component and at least one base note component at least partially fills the pores of the pulp base material. A release rate of the at least one top note component is modulated by the pulp base material, and a release rate of the at least one base note component is enhanced by the pulp base material.

Abstract: Disposable absorbent articles assembled from a collection of components using an adhesive comprising an amorphous polyolefin composition and a heterophase polyolefin composition comprising amorphous character and crystalline blocks.

Abstract: A radiopaque composition with low viscosity and increased photopolymerizability for application or filling of hollow structures is disclosed. Moreover, a method to apply and monitor the application and/or the photopolymerization of the composition are presented.

Abstract: Described is a process for making a dry and stable hemostatic composition, said process comprising a) providing a first component comprising a dry preparation of a coagulation inducing agent, b) providing a second component comprising a dry preparation of a biocompatible polymer suitable for use in hemostasis, c) providing said first component and said second component in a combined form in a final container, c1) either by filling said first component and said second component into said final container so as to obtain a dry mixture in said final container, c2) or by providing said first component or said second component in said final container and adding said second component or said first component so as to obtain a combination of said first component with said second component in said final container, d) finishing the final container to a storable pharmaceutical device containing said first component and said second component in a combined form as a dry and stable hemostatic composition.

Abstract: A biocompatible, covalently cross-linked, polymer that is obtained by reacting an electrophilically activated polyoxazoline (EL-POX) with a nucleophilic cross-linking agent is disclosed. The EL-POX comprises m electrophilic groups; and the nucleophilic cross-linking agent comprises n nucleophilic groups, wherein the m electrophilic groups are capable of reacting with the n nucleophilic groups to form covalent bonds; wherein m?2, n?2 and m+n?5; wherein at least one of the m electrophilic groups is a pendant electrophilic group and/or wherein m?3; and wherein to the EL-POX comprises an excess amount of electrophilic groups relative to the amount of nucleophilic groups contained in the nucleophilic cross-linking agent. Biocompatible medical products and kits comprising the cross-linked POX-polymers are also disclosed.

Abstract: A developable hyaluronic acid microspherical embolic agent includes a hyaluronic acid and an X-ray opaque contrast material; wherein the hyaluronic acid is a modified hyaluronic acid, wherein a modifying method for preparing the modified hyaluronic acid is cross-linking, grafting, esterification, or recombination, and is preferably cross-linking.

Abstract: The present invention relates to a medical dressing, in particular to a heparin sodium supported hydrogel sustained-release paster. The inventive heparin sodium supported hydrogel sustained-release paster includes a fixing layer and a backing layer and a hydrogel functional layer successively arranged on the fixing layer. The hydrogel functional layer is made up of hydrophilic high-molecular compound, heparin sodium and aqueous transdermal absorbefacient solution to through high-energy ray radiation or freeze-thaw cycle or combination of high-energy ray radiation and freeze-thaw cycle. The invention has the advantages as follows: the flake solid hydrogel material, synthesized by hydrophilic high-molecular compound with high biosecurity, has features of high biosecurity, high moisture content, compact molecular structure, controllable is water loss rate and prolonged service life.

Abstract: A bone graft composition promoting osteogenic capacity is provided. The bone graft composition includes an osteoinductive component including statins and a biodegradable polymer and an osteoconductive matrix including a biodegradable calcium phosphate ceramic, wherein the amount of the calcium phosphate ceramic is about 70 to 95 wt % based on the total weight of the bone graft composition. The bone graft composition can achieve the optimal release control characteristics of the statins in the osteoinductive component.

Abstract: Disclosed herein is a composition comprising stimulated biological material derived from an interface compartment, wherein the composition is capable of augmenting the generation or healing of a native tissue when administered to a subject in need thereof.

Abstract: Tissue repair compositions, particularly bone repair compositions, containing demineralized bone fragments and homogenized connective tissues, and methods for making the same. The compositions can be used in the form of an injectable gel, an injectable paste, a paste, a putty, or a rehydratable freeze-dried form.

Abstract: A method for preparing corneal tissue for applications predominantly in transplantation, and to the use of a solution for decellularizing corneal tissue. Methods of transplanting corneal tissue.

Abstract: Systems and methods that establish a pressure differential across a tissue wall to encourage complete decellularization of the wall are described. The methods can be utilized for decellularization of blood vessel tissue including heart valves and surrounding tissues. The methods and systems can essentially completely decellularize the treated tissue segments. Systems can be utilized to decellularize one or multiple tissue segments at a single time.

Abstract: Tissue products lacking a desired percentage of immunogenic epitopes, such as galactose alpha-1,3 galactose epitopes, are provided. Methods of making and using the tissue products are also provided.

Abstract: Disclosed herein is a composition comprising a stimulated heterogeneous mammalian tissue interface cell aggregate that is capable of producing functional polarized tissue when administered to a subject in need thereof.

Abstract: A tissue engineered periosteum for a patient comprising a sheet of stem cells. A method of repairing bone injury on a patient comprising implanting into the patient an engineered bone graph comprising a scaffold wrapped in a tissue engineered periosteum. A tissue engineered bone graph comprising a scaffold and a tissue engineered periosteum wrapped around an exterior of the scaffold.

Abstract: A method of treating a spinal disk according to the present invention can include inserting an alloplastic bulking agent into the spinal disk to treat the defect. The alloplastic bulking agent has a plurality of microparticles and a suspending agent comprising hyaluronic acid. The bulking agent results in at least one of sealing the defect, increasing a pressure of the disk, increasing a height of the disk, improving stability of the disk and improving structural integrity of the disk.

Abstract: The invention is directed to a multilayered drug eluting biodegradable foam comprising at least two layers, wherein each layer independently comprises a polymer and wherein at least one of said layers is a drug-comprising layer, which comprises at least one drug that is mixed with the polymer in said drug-comprising layer.

Abstract: A method for making an NO-releasing polymeric composition, a discrete RSNO adduct is dissolved in a solvent to form a discrete RSNO adduct solution. A polymer material is soaked in the discrete RSNO adduct solution for a predetermined time to swell the polymer material and impregnate the polymer material with the discrete RSNO adduct.

Abstract: There is disclosed a substrate with an electron donating surface, characterized in having metal particles on said surface, said metal particles comprising palladium and at least one metal selected from the group consisting of gold, ruthenium, rhodium, osmium, iridium, and platinum, wherein the amount of said metal particles is from about 0.001 to about 8 ?g/cm2.